Diasome’s liver‑directed insulin moves to phase III
The company reports promising phase IIb data and is preparing a phase III trial for its hepatocyte‑targeted insulin.
19 Oct 2026 0 reads Compiled with AI
#Diasome #Type 1 diabetes #HDV
Diasome, a New Orleans‑based biotech, sees type 1 diabetes as an unmet need because the only approved treatment remains insulin injections and daily blood‑sugar monitoring.
The company is developing a next‑generation insulin that targets liver cells to improve glucose control.
Hepatocyte‑Targeted Delivery
The HDV™ platform is a phospholipid bilayer disc that carries insulin to hepatocytes through the portal vein. It mimics natural cell membranes, binds insulin lispro, and uses a negative surface charge to attract positively charged proteins.
In a 25‑week phase IIb study, 226 adults with type 1 diabetes received either standard insulin lispro or HDV‑insulin. The new formulation lowered A1C similarly to lispro, reduced severe hypoglycaemia events, and had fewer serious adverse events.
Diasome is finalising its phase III plan, choosing protocols, power calculations, and the insulin version to use. The company will soon discuss the pivotal program with the FDA.
Other firms are also advancing type 1 diabetes therapies, such as Sanofi’s expanded label for Tzield and Eli Lilly’s planned trials of tirzepatide. The market could grow billions if a liver‑directed insulin gains approval.